An assay that may predict the development of IgG enhancing allergen-specific IgE binding during birch immunotherapy

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 68, Issue 9, 2013, Pages 1199-1202

  Selb, R ^a   Eckl Dorna, J ^a   Vrtala, S ^b   Valenta, R ^b   Niederberger, V ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Bet v 1; birch pollen allergy; enhancing IgG antibodies; immunotherapy; recombinant allergen

Indexed keywords

BET V 1; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; POLLEN EXTRACT; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; BIRCH; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; SKIN SENSITIVITY;

BET V 1; BIRCH POLLEN ALLERGY; ENHANCING IGG ANTIBODIES; IMMUNOTHERAPY; RECOMBINANT ALLERGEN;

ADULT; ALLERGENS; ANTIBODY SPECIFICITY; ANTIGENS, PLANT; BETULA; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROGNOSIS; RHINITIS, ALLERGIC, SEASONAL; YOUNG ADULT;

EID: 84884987212     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12204     Document Type: Article

References (12)

1. Swoboda I, Twaroch T, Valenta R,. Tree pollen allergens. In:, Kaliner MA, Lockey RF, editors. Allergens and allergen immunotherapy, 4th edn. New York: Informa Healthcare, 2008; 87-105.
2. Gieras A, Cejka P, Blatt K, Focke-Tejkl M, Linhart B, Flicker S, et al. Mapping of conformational IgE epitopes with peptide-specific monoclonal antibodies reveals simultaneous binding of different IgE antibodies to a surface patch on the major birch pollen allergen, Bet v 1. J Immunol 2011; 186: 5333-5344.
3. Pauli G, Larsen TH, Rak S, Horak F, Pastorello E, Valenta R, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008; 122: 951-960.
4. Visco V, Dolecek C, Denepoux S, Le Mao J, Guret C, Rousset F, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol 1996; 157: 956-962.
5. Denépoux S, Eibensteiner PB, Steinberger P, Vrtala S, Visco V, Weyer A, et al. Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. FEBS Lett 2000; 465: 39-46.
6. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, Valent P, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (Suppl 2): 14677-14682.
7. Vrtala S, Akdis CA, Budak F, Akdis M, Blaser K, Kraft D, et al. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies. J Immunol 2000; 165: 6653-6659.
8. Valenta R, Ferreira F, Focke-Tejkl M, Linhart B, Niederberger V, Swoboda I, et al. From allergen genes to allergy vaccines. Annu Rev Immunol 2010; 28: 211-241.
9. Valenta R, Linhart B, Swoboda I, Niederberger V,. Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens. Allergy 2011; 66: 775-783.
10. Shamji MH, Ljorring C, Francis JN, Calderon MA, Larche M, Kimber I, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy 2012; 67: 217-226.
11. Marth K, Breyer I, Focke-Tejkl M, Blatt K, Shamji M, Layhadi J, et al. A non-allergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG towards IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol 2013; 190: 3068-3078.
12. Focke-Tejkl M, Valenta R,. Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol 2012; 12: 555-563.